FCCC LOGO Faculty Publications
Chen P , Balachandran S
Development of interferon gamma-based immunocytokines targeting renal cancer
Oncoimmunology. 2013 Jul 1;2(7) :e24964
PMID: 24073376    PMCID: PMC 3782162    URL: https://www.ncbi.nlm.nih.gov/pubmed/24073376
Back to previous list
Abstract
Advanced renal cancer is an incurable malignancy in need of novel therapeutic avenues. We have generated interferon gamma (IFNgamma)-based fusion antibodies (immunocytokines) that target CD70, a putative biomarker of renal cancer. These immunocytokines efficiently labeled renal cancer cells, and, when combined with the proteasome inhibitor bortezomib, killed them by activating a RIP1-dependent necrotic pathway.
Notes
Chen, Peirong Balachandran, Siddharth eng Oncoimmunology. 2013 Jul 1;2(7):e24964. doi: 10.4161/onci.24964. Epub 2013 May 16.